Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S2.15
P/E—
Fwd P/E13.38
PEG1.11
52W— – —
RSI—
Target$195.67 (+10.0%)
Beta0.28
Div2.38%
Loading chart…
RSI ()
Loading patterns…
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 45
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
7Bullish
5Bearish
0Neutral
Key Signals 3
▲ Double Bottom
Major reversal
2026-06-05 · $149.68
Two lows ~$141.48 — bullish reversal confirmed
Learn more →
▲ Double Bottom
Major reversal
2026-06-26 · $152.55
Two lows ~$141.12 — bullish reversal confirmed
Learn more →
▼ Double Top
Major reversal
2026-06-17 · $142.13
Two peaks ~$151.12 — bearish reversal confirmed
Learn more →
Momentum Signals 9
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ Bull Flag
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$195.67
+10.0% upside
Low $170
—
High $225
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
46.94%Last 12 Months
Operating Margin
15.73%Last 12 Months
Return on Equity
6.61%Last 12 Months
Revenue Growth
5.40%Year over Year
Free Cash Flow
4.48BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
68.84Most Recent Quarter
Current Ratio
0.86Most Recent Quarter
Cash
709.00MMost Recent Quarter
Total Debt
16.81BMost Recent Quarter
Net Debt
—Most Recent Quarter
How BDX Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 48.44B |
| Enterprise Value | 64.54B |
| Trailing P/E | 30.51 |
| Forward P/E | 13.38 |
| PEG Ratio (5yr) | 1.11 |
| Price/Sales (ttm) | 2.15 |
| Price/Book (mrq) | 1.98 |
| EV/Revenue | 2.87 |
| EV/EBITDA | 10.54 |
Share Statistics
| Avg Vol (3m) | 2.10M |
| Shares Outstanding | 272.39M |
| Float | 271.66M |
| % Held by Insiders | 0.43% |
| % Held by Institutions | 99.71% |
| Short Ratio | 5.76 |
| Short % of Float | 4.47% |
Profitability
| Gross Margin | 46.94% |
| Operating Margin (ttm) | 15.73% |
| Profit Margin | 4.19% |
| Return on Assets (ttm) | 4.34% |
| Return on Equity (ttm) | 6.61% |
Income Statement
| Revenue (ttm) | 22.48B |
| Revenue Growth (yoy) | 5.40% |
| Gross Profit (ttm) | 10.55B |
| EBITDA | 6.12B |
| Net Income (ttm) | 1.65B |
| Diluted EPS (ttm) | 5.83 |
| EPS Growth (yoy) | -31.40% |
Balance Sheet
| Total Cash (mrq) | 709.00M |
| Total Debt (mrq) | 16.81B |
| Debt / Equity (mrq) | 68.84 |
| Current Ratio (mrq) | 0.86 |
| Book Value / Share | 89.64 |
| Operating CF (ttm) | 3.34B |
| Free Cash Flow (ttm) | 4.48B |
Trading & Dividends
| Beta (5Y) | 0.28 |
| 50-Day MA | 171.46 |
| 200-Day MA | 160.22 |
| Fwd Dividend Yield | 2.38% |
| Payout Ratio | 72.49% |
Income
Dividend Yield
2.38%Last 12 Months
Annual Rate
4.20Forward
Payout Ratio
72.49%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 72.49%
Monthly Dividends
Ownership Breakdown
Institutional 99.71%
Insider 0.43%
Short Interest
4.47% of float
Moderate
Institutional 13F Holdings
Famous investors who disclosed a position in BDX in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|